Evidence map›Paper›PMID 39746910›Full record

ArticleNature communications2025

The molecular reach of antibodies crucially underpins their viral neutralisation capacity.

Anna Huhn, Daniel Nissley, Daniel B Wilson, Mikhail A Kutuzov, Robert Donat, Tiong Kit Tan, Ying Zhang, Michael I Barton, Chang Liu, Wanwisa Dejnirattisai and 9 more

Erratum issuedAbstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Anna HuhnSir William Dunn School of Pathology, University of Oxford, Oxford, UK.
Daniel NissleyOxford Protein Informatics Group, Department of Statistics, University of Oxford, Oxford, UK.
Daniel B WilsonSir William Dunn School of Pathology, University of Oxford, Oxford, UK.
Mikhail A KutuzovSir William Dunn School of Pathology, University of Oxford, Oxford, UK.ORCID 0000-0003-3386-4350
Robert DonatMRC Translate Immune Discovery Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID 0000-0003-3432-5690
Tiong Kit TanMRC Translate Immune Discovery Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID 0000-0001-8746-8308
Ying ZhangDepartment of Mathematics and Statistics, Boston University, Boston, Massachusetts, USA.
Michael I BartonSir William Dunn School of Pathology, University of Oxford, Oxford, UK.ORCID 0000-0002-9263-6481
Chang LiuWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Wanwisa DejnirattisaiWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Piyada SupasaWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Juthathip MongkolsapayaWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0003-3416-9480
Alain TownsendMRC Translate Immune Discovery Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
William JamesJames & Lillian Martin Centre, Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.ORCID 0000-0002-2506-1198
Gavin ScreatonWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-3549-4309
P Anton van der MerweSir William Dunn School of Pathology, University of Oxford, Oxford, UK.ORCID 0000-0001-9902-6590
Charlotte M DeaneOxford Protein Informatics Group, Department of Statistics, University of Oxford, Oxford, UK. deane@stats.ox.ac.uk.ORCID 0000-0003-1388-2252
Samuel A Isaacson *Department of Mathematics and Statistics, Boston University, Boston, Massachusetts, USA. isaacsas@bu.edu.ORCID 0000-0002-7543-8619
Omer Dushek *Sir William Dunn School of Pathology, University of Oxford, Oxford, UK. omer.dushek@path.ox.ac.uk.ORCID 0000-0001-5847-5226

Funding

Wellcome Trust
6 · The paper itself

Abstract

Key functions of antibodies, such as viral neutralisation, depend on high-affinity binding. However, viral neutralisation poorly correlates with antigen affinity for reasons that have been unclear. Here, we use a new mechanistic model of bivalent binding to study  >45 patient-isolated IgG1 antibodies interacting with SARS-CoV-2 RBD surfaces. The model provides the standard monovalent affinity/kinetics and new bivalent parameters, including the molecular reach: the maximum antigen separation enabling bivalent binding. We find large variations in these parameters across antibodies, including reach variations (22-46 nm) that exceed the physical antibody size (~15 nm). By using antigens of different physical sizes, we show that these large molecular reaches are the result of both the antibody and antigen sizes. Although viral neutralisation correlates poorly with affinity, a striking correlation is observed with molecular reach. Indeed, the molecular reach explains differences in neutralisation for antibodies binding with the same affinity to the same RBD-epitope. Thus, antibodies within an isotype class binding the same antigen can display differences in molecular reach, substantially modulating their binding and functional properties.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19Immunoglobulin GSARS-CoV-2Spike Glycoprotein, CoronavirusAntibody AffinityAntigens, ViralEpitopesHumansKineticsProtein BindingAntibodies, NeutralizingAntibodies, ViralAntigens, ViralEpitopesImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID39746910
PMCPMC11695720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.